Lifeng Zhang

Dr. Lifeng Zhang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2023 in Heliyon
Verified
Journal Article
Open access
HPHaiyan Pan
Haiyan Pan
ZSZebin Shi
Zebin Shi
LGLei Gao
Lei Gao
LZLi Zhang
Li Zhang
SWShuzhang Wei
Shuzhang Wei
LZLifeng Zhang
Lifeng Zhang
Cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) is an immunosuppressive checkpoint that is involved in the development and metastasis of cancers. Several studies revealed that CTLA-4 rs231775A/G polymorphism may be associated with the risk of cancer in some populations, but the conclusions of these studies are not consistent. We conducted a pooled analysis with eligible studies to explore the association between the CTLA-4 rs231775 variant and cancer risk. Additionally, we used in silico tools to evaluated the expression of CTLA-4 on urinary system cancer. Moreover, we adopted the enzyme-linked immunosorbent assay (ELISA), and Gene Set Enrichment Analysis (GSEA) to investigate the effects of CTLA-4 on bladder cancer (BLCA). In total, 92 case-control studies involving 29,987 patients with cancer and 36,484 healthy individuals (controls) were included in the pooled analysis. In the stratified analysis based on cancer type, the rs231775 A/G polymorphism was associated with increased bladder cancer risk in the heterozygote contrast model (OR = 1.23, 95% CI = 1.01–1.51, P = 0.040). The race-stratified analysis revealed that East Asians with the GG genotype had a 12% lower risk of developing cancer than those with the GA + AA genotype (95% CI = 0.81–0.95, P = 0.001). The in silico analysis showed that CTLA-4 expression was augmented in patients with BLCA. The ELISA results revealed that CTLA-4 expression was reduced in patients with BLCA carrying the AA genotype. Several signaling pathways, including cytokine-cytokine receptor interactions and T-cell receptor signaling, were associated with CTLA-4 expression. The CTLA-4 rs231775 A/G polymorphism is associated with cancer risk in East Asian population. This polymorphism is especially associated with BLCA.

21 November 2023 in International Journal of Genomics
Verified
Journal Article
Open access
PDF file
SWShuzhang Wei
Shuzhang Wei
YCYin Chen
Yin Chen
XSXiaokai Shi
Xiaokai Shi
LZLi Zuo
Li Zuo
LZLifeng Zhang
Lifeng Zhang
Background. Currently, the role of oncostatin M (OSM) in clear cell renal cell carcinoma (ccRCC) has not been investigated. This study will explore the impact of OSM on ccRCC expression, prognosis, and cell function. Materials and Methods. In this study, we used The Cancer Genome Atlas (TCGA) database to evaluate OSM expression characteristics, pathogenic factor distribution, and prognostic aspects in ccRCC. We also combined this analysis with qRT-PCR to verify OSM mRNA expression levels at the tissue level. Then, the effects of OSM on the proliferation, invasion, and migration abilities of ccRCC cells were explored through CCK8, Transwell, Western blotting, and immunofluorescence experiments. Finally, the oncogenic mechanisms associated with OSM in ccRCC were explored through signaling pathway enrichment and single-cell analysis. Results. The results demonstrated that OSM was significantly more expressed in ccRCC than in normal tissues. According to the survival analysis, OSM in ccRCC was considerably worse in the group with high expression than in the group with low expression. Also, the univariate and multivariate Cox analyses of clinical characteristics show that OSM in ccRCC may be able to predict a poor prognosis on its own as a biomarker. In vitro cellular experiments demonstrated that high OSM expression had no discernible impact on ccRCC cell proliferation compared to the control group, but it did promote tumor cell invasion and migration. Signaling pathways and single-cell analysis revealed that OSM might promote ccRCC invasion and migration through M2 macrophages. Conclusion. In conclusion, OSM may serve as an independent poor prognostic biomarker in ccRCC and promote tumor cell invasion and migration. This discovery is expected to provide a new therapeutic target for patients with recurrent and metastatic ccRCC.

8 May 2023 in PPAR Research
Verified
Journal Article
Open access
PDF file
CLChao Lu
Chao Lu
SGShenglin Gao
Shenglin Gao
LZLi Zhang
Li Zhang
XSXiaokai Shi
Xiaokai Shi
YCYin Chen
Yin Chen
LZLifeng Zhang
Lifeng Zhang
Background. The Nuclear protein 1 gene was first discovered in acute pancreatitis and functions as an oncogene in cancer progression and drug resistance. However, the role of Nuclear protein 1 in bladder transitional cell carcinoma (BTCC) is still unclear. Methods. The Cancer Genome Atlas database and immunohistochemical analysis were adopted to evaluate Nuclear protein 1 expression in BTCC. We applied lentivirus-mediated small-interfering RNA to down-regulate the expression of Nuclear protein 1 in BTCC cell lines. We further performed an Affymetrix microarray and Gene Set Enrichment Analysis (GSEA) to assess the genes and signaling pathways related to Nuclear protein 1. Results. We found that Nuclear protein 1 expression was up-regulated in BTCC and positively related to the degree of BTCC malignancy. Compared with Caucasian patients with BTCC, Nuclear protein 1 expression was attenuated in Asian patients. The Affymetrix microarray showed that lipopolysaccharide was the upstream regulatory factor of Nuclear protein 1 in BTCC. The GSEA indicated that Nuclear protein 1 expression was associated with signaling pathways in cancer, peroxisome proliferator-activated receptor (PPAR) pathways, and RNA degradation. The expression of Nuclear protein 1 was negatively correlated with PPARG ( , ), but not with PPARA ( , ) and PPARD ( , ). Conclusions. The study findings indicate that Nuclear protein 1 is positively associated with the malignancy degree of BTCC and that Nuclear protein 1 expression is negatively correlated with PPARG.

5 October 2023 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
HWHai Wang
Hai Wang
LGLei Gao
Lei Gao
YCYin Chen
Yin Chen
LZLei Zhang
Lei Zhang
YBYu Bai
Yu Bai
HSHeyun Sun
Heyun Sun
Bladder transitional cell carcinoma (BTCC) forms more than 90% of bladder cancer cases. It brings challenges to the early diagnosis and therapy of BTCC, due to lack of efficient screening biomarkers. We used weighted gene co‐expression network analysis (WGCNA) combined competing endogenous RNA (ceRNA) network construction depending on TCGA datasets to investigate potential hub genes and regulatory pathways associated with occurrence and progression of BTCC. We further used real‐time polymerase chain reaction (RT‐PCR) to validate the relative expression genes correlated with BTCC. By WGCNA, the gene co‐expression module with 11 genes was found corelated with BTCC tumour stage and prognosis after survival analyses. Ultimately, we put 100 highly stage‐related genes into the above constructed ceRNA network and then constructed another new network. Among them, all elements in AC112721.1/LINC00473/AC128709.1‐hsa‐mir‐195‐RECK and LINC00460‐hsa‐mir‐429‐ZFPM2 axes were simultaneously corelated with overall survival. RT‐PCR showed that AKAP12 was downregulated in tumour tissues. The hub genes screened out in the present study may provide ideals for further treatment on BTCC.

17 April 2026 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
HDHannuo Deng
Hannuo Deng
YMYuanyuan Mi
Yuanyuan Mi
LZLei Zhang
Lei Zhang
YTYuchen Tan
Yuchen Tan
GHGuangming He
Guangming He
JPJie Peng
Jie Peng
NUPR1 is a pro‐tumorigenic factor in bladder cancer (BLCA), but the mechanisms governing its protein stability remain poorly defined. Here, we identified ARIH2 as an E3 ubiquitin ligase that interacts with NUPR1 in BLCA cells through immunoprecipitation‐mass spectrometry (IP‐MS), co‐immunoprecipitation (Co‐IP), and immunofluorescence analyses. ARIH2 overexpression reduced NUPR1 abundance and inhibited BLCA cell proliferation and migration while enhancing apoptosis, whereas ARIH2 knockdown increased NUPR1 expression and promoted malignant phenotypes. Mechanistically, ARIH2 depletion prolonged NUPR1 protein stability and reduced its ubiquitination, indicating that ARIH2 negatively regulates NUPR1 through ubiquitin‐mediated degradation. Moreover, NUPR1 overexpression suppressed ferroptosis, as reflected by increased GPX4 and SLC7A11, decreased ACSL4, reduced lipid peroxidation, and diminished Fe 2+ accumulation, while NUPR1 knockdown exerted the opposite effects. ARIH2 knockdown mimicked the ferroptosis‐resistant phenotype induced by NUPR1 upregulation, supporting that ARIH2 modulates ferroptosis through NUPR1. Bioinformatic and experimental analyses further showed that NUPR1 was associated with immunosuppressive infiltration and promoted M2 macrophage polarization. Together, our findings uncover an ARIH2–NUPR1 regulatory axis that drives BLCA progression by suppressing ferroptosis and favouring an immunosuppressive microenvironment, highlighting this pathway as a potential therapeutic target in BLCA.

2 November 2024 in Archives of Medical Science
Verified
Journal Article
Closed access
ZSZebin Shi
Zebin Shi
HSHeyun Sun
Heyun Sun
WZWei Zhang
Wei Zhang
WZWenyuan Zhuang
Wenyuan Zhuang
XSXiaokai Shi
Xiaokai Shi
LZLifeng Zhang
Lifeng Zhang
Introduction: SNHG3 (small nucleolar RNA host gene 3) is a long non-coding RNA (lncRNA) that plays a pivotal role in cellular regulation. It is intricately involved in modulating the cell cycle, enhancing cell proliferation, and inhibiting apoptosis. These functions position SNHG3 as a significant contributor to oncogenic processes. Given its substantial influence on tumorigenesis, elucidating the exact molecular mechanisms through which SNHG3 operates is paramount. Comprehensive understanding of SNHG3's interactions and pathways is not only critical for advancing our knowledge of cancer biology but also holds immense potential for identifying novel therapeutic targets. By targeting the regulatory networks associated with SNHG3, new strategies can be developed for the effective treatment of malignancies where SNHG3 is implicated.Material and methods: We investigated the role of lncRNA SNHG3 in promoting prostate cancer (PCa) proliferation and invasion. Using TCGA data, we assessed SNHG3 expression in cancer/adjacent tissue, Gleason score, biochemical recurrence, and overall survival. SNHG3 expression was manipulated in four cell types via siRNA interference/over-expression. Various experiments were conducted to confirm SNHG3's role in PCa, including clone ability, apoptosis, migration, Transwell invasion, and subcutaneous tumor experiments in nude mice.Results: In PCa, SNHG3 was highly expressed, especially in Gleason score >7 patients, correlating with shorter overall survival. Interfering with SNHG3 using a plasmid reduced proliferation, increased apoptosis, and decreased migration and tumor growth. Conversely, SNHG3 overexpression yielded opposite results.Conclusions: The lncRNA SNHG3 promotes PCa proliferation and invasion while inhibiting cell apoptosis.